Anergia-anhedonia by Lithium-induced Phosphorus Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-01

Study Completion Date

2024-04-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lithium (Li+) is prescribed to 1‰ of the French population (\~ 60,000 patients). More than half of patients describe subjective symptoms linked to Li+ (SSL) similar to those of chronic fatigue syndrome: muscle weakness, fatigability, cognitive disorders, emotional blunting. SSL are the 2nd cause of stopping Li+ (28%), just behind kidney problems (30%).

In animals, the administration of lithium (Li+) increases the urinary excretion of phosphate (Pi) by 6, inducing phosphate diabetes (DPi). However, idiopathic forms of DPi explain up to 10-15% of chronic fatigue syndromes and these disappear when supplementing with Pi (± vitamin D).

In humans, the introduction of Li+ leads to a reduction in serum phosphate but we have not found any publication on the possible induction of DPi or on a possible link between DPi and SSL.

However, the dosages necessary to detect a DPi are carried out during the annual follow-up assessment of patients on Li+. All you have to do is calculate the standardized maximum reabsorption rate of Pi (TmPi) to make the diagnosis! Finally, if the patients presenting with DPi turn out to be the same as those who complain of SSL, we can imagine that correcting the first by simple supplementation with Pi (± vitamin D) could provide relief.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lithium in Multiple System Atrophy

NCT00997672

Multiple System Atrophy

TERMINATED PHASE2

Modafinil for Treatment of Fatigue in ALS Patients

NCT00614926

Fatigue

COMPLETED PHASE4

Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment

NCT06789783

Cornelia De Lange Syndrome

RECRUITING PHASE2/PHASE3

Dantrolene in Statin-induced Myopathy

NCT06966843

Statins Induced Myopathy

NOT_YET_RECRUITING PHASE2/PHASE3

Tolerance and Efficacy Nicotinamide (vitamin B3) in Dominant Optic Atrophy OPA1

NCT06007391

Nicotinamide Adverse Reaction

RECRUITING PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of the study is to determine the prevalence of hypophosphatemia, DPi and SSL in a population of ambulatory patients controlled on Li+ (\> 6 months).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mood Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Major subject (≥ 18 years old)
* Man or woman
* Subject balanced on Li+ (\> 6 months, regardless of the underlying pathology).
* Outpatient monitoring by one of the members of CEDRA (Alsace expert center for resistant depression).
* Subject not opposing, after information, the reuse of their data for the purposes of this research